PMID- 34527074
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20220426
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Print)
IS  - 1748-670X (Linking)
VI  - 2021
DP  - 2021
TI  - Efficacy and Safety of Immunosuppressant Therapy for Noninfectious Uveitis: A 
      Systematic Review and Meta-Analysis.
PG  - 1933604
LID - 10.1155/2021/1933604 [doi]
LID - 1933604
AB  - OBJECTIVE: To analyze efficacy and safety of immunosuppressant therapy for 
      noninfectious uveitis. METHODS: A network search of PubMed, ResearchGate, and 
      EMBASE databases was conducted for relative literature and studies from the 
      inception of each database to April 2021. Primary outcomes were efficacy and time 
      to treatment failure of immunosuppressant for noninfectious uveitis. Secondary 
      outcome was incidence of adverse events (AEs). Cochrane risk of bias tool was 
      used to assess risk of bias of included studies. Fixed effects model or random 
      effects model was implemented to assess statistical heterogeneity. Subgroup 
      analysis was employed to analyze heterogeneous sources. RESULTS: Eight studies 
      were deemed eligible for inclusion with a total of 848 patients. Six studies were 
      randomized controlled trials (RCTs). Among them, a single-blind RCT had 
      relatively high measurement bias and performance bias. Immunosuppressant 
      presented favorable efficacy for noninfectious uveitis than placebo, and RR was 
      1.43 (95% CI: 1.12-1.82). Immunosuppressant for noninfectious uveitis prolonged 
      the time before failure, and HR was 0.43 (95% CI: 0.32-0.54). AEs increased after 
      immunosuppressant was applied. Compared with immunosuppressant, RR of AEs with 
      placebo was 0.88 (95% CI: 0.71-1.08). CONCLUSION: Immunosuppressant contributed 
      to controlling progression of noninfectious uveitis to some extent. Compared with 
      placebo, it increased incidence of AEs. More studies with low heterogeneity are 
      warranted for stronger evidence in clinical.
CI  - Copyright (c) 2021 Haihong Zuo et al.
FAU - Zuo, Haihong
AU  - Zuo H
AUID- ORCID: 0000-0002-9073-0538
AD  - Department of Ophthalmology, Tianjin Haihe Hospital, Tianjin 300350, China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Stomatology, Tianjin Haihe Hospital, Tianjin 300350, China.
FAU - Yan, Yuqing
AU  - Yan Y
AD  - Department of Ophthalmology, Tianjin Haihe Hospital, Tianjin 300350, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210904
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (TNF protein, human)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Bias
MH  - Computational Biology
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Outcome Assessment, Health Care
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Safety
MH  - Treatment Failure
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
MH  - Uveitis/*drug therapy
PMC - PMC8437623
COIS- The authors declare no conflicts of interest.
EDAT- 2021/09/17 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/09/04
CRDT- 2021/09/16 07:07
PHST- 2021/05/06 00:00 [received]
PHST- 2021/08/10 00:00 [accepted]
PHST- 2021/09/16 07:07 [entrez]
PHST- 2021/09/17 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/09/04 00:00 [pmc-release]
AID - 10.1155/2021/1933604 [doi]
PST - epublish
SO  - Comput Math Methods Med. 2021 Sep 4;2021:1933604. doi: 10.1155/2021/1933604. 
      eCollection 2021.